Selskabets formål er at drive virksomhed indenfor handel og industri.
| Year | Revenue | Profit/Loss | Total Assets | Equity | Employees | Report |
|---|---|---|---|---|---|---|
| 2024 | 479.1 mio. | 14.6 mio. | 150.6 mio. | 56.3 mio. | 18 | |
CVR: 30077008
Secondary names: McNeil Esbjerg ApS;, Scan-Gum ApS, Pharmacia Esbjerg ApS
Previous names: PFIZER DENMARK PCH ApS
Compared to 406 companies in Engroshandel med medicinalvarer og sygeplejeartikler
Comparison is based on industry median values
Heidi Gusfre Skårdal joined as ADM. DIR.
Jukka Arlak Karppinen joined as director
Andreas Balslev Nørkjær joined as director
John Jensen left as ADM. DIR.
Heidi Gusfre Skårdal left as director
Companies in the same industry and area
CVR 43126261
CVR 45449688
CVR 37720089
CVR 27341357
CVR 27652808
The financial health of MCNEIL DENMARK ApS appears stable, with consistent revenue generation and profitability over recent years. In 2024, the company reported revenue of 479.14 million DKK and a profit of 14.58 million DKK, reflecting a slight decline in revenue from 2023 but an increase in profit. Equity has significantly improved from 27.32 million DKK in 2022 to 56.28 million DKK in 2024, indicating a strengthening balance sheet. While profit margins have fluctuated, the overall trend shows resilience, positioning the company favorably within the medicinal and healthcare wholesale industry. However, the stability of revenue and profit in the face of slight declines may warrant monitoring for future growth opportunities.
AI-generated summary
companydata.dk